Dr Shilpa Gupta

Dr. Shilpa Gupta is the Director of the Genitourinary Medical Oncology at Taussig Cancer Institute and Co-Leader of the Genitourinary Oncology Program at Cleveland Clinic. Dr. Gupta’s research interests are novel drug development and understanding biomarkers of response and resistance to therapies in bladder cancer. Dr. Gupta has led several Investigator Initiated Trials in Genitourinary Cancers and has leadership roles in NCI trials and is Chair of an Alliance led phase 3 trial in Bladder Cancer, Co-Chair of SWOG S1206 trial in Prostate Cancer and SWOG champion of the Alliance A031701 trial in Bladder Cancer. She is Principal Investigator of 2020 Department of Defense Idea Award to study the biomarkers of response and resistance to immunotherapy in bladder cancer and Co-Principal Investigator of Department of Defense Team Translational Science Award to study immunotherapy combination strategies to overcome resistance in bladder cancer. Dr. Gupta is the Co-Chair of the Hoosier Cancer Research Network (HCRN) Genitourinary Working Group and Co-Chair of the Case Comprehensive Cancer Center PRMC committee.

Her research work has been published in peer-reviewed journals including the Journal of Clinical oncology, Lancet Oncology, Clinical Cancer Research, European oncology, among others. She is the author for the AUA core curriculum for penile cancer and serves on the NCCN Guidelines Panel for Prostate Cancer. Dr. Gupta is active in several professional organizations including the American Society of Clinical Oncology (ASCO), American Urologic Association (AUA), American Association of Cancer Research (AACR), Society of Urologic Oncology (SUO), Society of Immunotherapy for cancer (SITC), Bladder Cancer Advocacy Network (BCAN), Prostate Cancer Foundation (PCF) and the European society of Medical Oncology (ESMO).